EXHIBIT 99.1 Precision Drilling Announces 2024 Third Quarter Unaudited Financial Results Precision Drilling Corporation ("Precision" or the "Company") (TSX:PD; NYSE:PDS) delivered strong third quarter financial results, demonstrating the resilience of the business and its robust cash flow potential. Year to date, Precision has already achieved the low end of its debt reduction target range and is well on track to allocate 25% to 35% of its free cash flow to share buybacks in 2024. Financial Highlights Opera ...

CALGARY, Alberta, Oct. 29, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnin ...

CALGARY, Alberta, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 third quarter results after the market closes on Tuesday, October 29, 2024, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, October 30, 2024. To participate in the conference call please register at the URL link below. Once registered, you will receive a dial-in number and a unique PIN, which will allow you to ask questions. https ...

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024 PRINCETON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system tar ...

Financial blogger, part-time investor. Bullish oil & gas, OFS/offshore, commodities, EMs. Bearish energy transition. My posts aren't investment advice, DYODD.Disclaimer: My articles, blog posts and comments on this platform do not constitute investment recommendations, but rather express my personal opinions and are for informational purposes only. I may be a CFA but I am not a registered investment advisor and none of my writings should be considered as investment advice. While I do my best to ensure I pre ...

I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I w ...

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. Precision Drilling Corporation (Precision or the Company) announced today that the Toronto Stock Exchange (the T ...

Core Insights - PDS Biotechnology Corporation is set to present updated data from the VERSATILE-002 trial, which evaluates the first-line treatment of Versamune® HPV in combination with KEYTRUDA® for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma at the ESMO Congress 2024 [1][2] Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers, as well as developing vaccines for infectious diseases [3] - The company plans to initiate a pivotal clinical trial in 2024 to advance its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [3] - Versamune® HPV, the company's lead investigational targeted immunotherapy, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate [3]

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York Cit ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being unde ...